Sign in
CompletedNo phase

Investigating Mild Cognitive Impairment in Patients And Controls With TD-fNIRS

Key facts

Who runs it
Kernel
Where
Carlsbad, Costa Mesa, Escondido, Los Angeles, Santa Ana, and Temecula, United StatesSee the 6 sites
Trial code
Status
Completed
People taking part
133 people enrolled
Started
25 Jul 2023
Ended
13 Jun 2024
Type of study
Observational, 2 groups
Treatments tested
  • fNIRS measurement
Record updated
3 July 2024

Who can take part

Age
55 years to 85 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Patients
  • Must have a diagnosis of MCI (amnesiac or non-amnesiac) as determined by clinician
  • Adults (older adults) between the ages of 55-85 years inclusive at time of enrollment
  • Ability to perform informed consent on their own
  • Fluent in English (speaking and reading); Healthy Controls
  • Adults (older adults) between the ages of 55-85 years inclusive at time of enrollment
  • Ability to perform informed consent on their own
  • Fluent in English (speaking and reading)

Who cannot take part

  • Current substance or alcohol dependence, and/or alcohol or substance abuse as determined by CAGE-AID assessment for drug and alcohol abuse. A score of 2 or higher would result in exclusion
  • Prior MCI or memory impairment diagnosis
  • Current substance or alcohol dependence, and/or alcohol or substance abuse as determined by CAGE-AID assessment for drug and alcohol abuse. A score of 2 or higher would result in exclusion
  • Alzheimer's or dementia diagnosis
  • Current or recent (in the past 6 months) chemotherapy and/or radiation for any cancer
  • Major medical illnesses and psychiatric conditions (other than MCI) including:; Severe/uncontrolled Diabetes, hypertension and hypothyroidism that could pose secondary causes of cognitive decline; Parkinson's disease; Motor neuron diseases; Multiple Sclerosis; Brain Tumor; Stroke; Encephalitis; Meningitis; Epilepsy; TBI with serious results (coma, unconscious for >2 hrs, or skull fracture); Current serious psychiatric conditions (bipolar disorder, schizophrenia, or psychosis); Healthy Controls
  • First-degree relative with dementia or clinically relevant memory problems
  • Alzheimer's or dementia diagnosis
  • Current or recent (in the past 6 months) chemotherapy and/or radiation for any cancer
  • Major medical illnesses and psychiatric conditions including:; Severe/uncontrolled Diabetes, hypertension and hypothyroidism that could pose secondary causes of cognitive decline; Parkinson's disease; Motor neuron diseases; Multiple Sclerosis; Brain Tumor; Stroke; Encephalitis; Meningitis; Epilepsy; TBI with serious results (coma, unconscious for >2 hrs, or skull fracture); Current serious psychiatric conditions (bipolar disorder, schizophrenia, or psychosis)
  • Patients
  • Has uncorrected major visual or auditory deficits that would prevent them from completing a study task
  • Has uncorrected major visual or auditory deficits that would prevent them from completing a study task

Where in United States

  • The Research Center of Southern CaliforniaCarlsbad, United States
  • BrainHealth SolutionsCosta Mesa, United States
  • The Research Center of Southern CaliforniaEscondido, United States
  • KernelLos Angeles, United States
  • Syrentis Clinical ResearchSanta Ana, United States
  • The Research Center of Southern CaliforniaTemecula, United States

About the trial

What the trial wants to find out

The goal of the proposed observational, multi-site study is to use fNIRS neurophysiological data recorded during a battery of tasks to detect MCI within a cohort consisting of patients and age-matched healthy controls. Furthermore, the investigators aim to explore whether they can measure the severity of MCI symptoms in the patient population. If successful, this approach enables clinicians to track the disease at its source-the brain; possibly allowing for earlier detection of MCI and its progression, and ultimately more efficient interventions.

The 2 groups in the trial

  • MCI Patients

    Adult participants who are seeking neurological assessments for Mild Cognitive Impairment (MCI) at a participating clinic/study site.

    Treatment: fNIRS measurement

  • Healthy Controls

    Healthy participants without a prior MCI or memory impairment diagnosis.

    Treatment: fNIRS measurement

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
IMPACT: Investigating Mild Cognitive Impairment in Patients And Controls With TD-fNIRS
Record updated
3 July 2024